Lantus, Insulin Glargine Newswire

Lantus, Insulin Glargine Newswire

Comprehensive Real-Time News Feed for Lantus, Insulin Glargine (generic).

Results 1 - 20 of 259 in Lantus, Insulin Glargine (generic)

  1. Lixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast...Read the original story

    Monday Jun 18 | Circulation

    From the Department of Internal Medicine, Diabetes Center From the Department of Internal Medicine, Diabetes Center From the Department of Internal Medicine, Diabetes Center Division of Pharmacology and Vascular Medicine, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, The Netherlands From the Department of Internal Medicine, Diabetes Center From the Department of Internal Medicine, Diabetes Center The prolonged treatment effects of a short-acting GLP-1RA , such as lixisenatide, on fasting and postprandial systemic hemodynamics in type 2 diabetes mellitus patients are unknown. In this secondary analysis, we included 34 overweight insulin glargine-treated type 2 diabetes mellitus patients .

    Comment?

  2. Sanofi (SNY) Upgraded by Zacks Investment Research to HoldRead the original story w/Photo

    Saturday Jun 16 | IntersportsWire

    According to Zacks, "Sanofi has several new products in its portfolio and candidates in its pipeline that can contribute to long-term growth. Particularly, we are optimistic on sales prospects of Dupixent, which could prove to be an important growth driver.

    Comment?

  3. Influence of preprandial vs. postprandial insulin glulisine on weight ...Read the original story

    Saturday Jun 16 | CiteULike

    Influence of preprandial vs. postprandial insulin glulisine on weight and glycaemic control in patients initiating basal-bolus regimen for type 2 diabetes: a multicenter, randomized, parallel, open-label study . Insulin therapy is commonly associated with weight gain.

    Comment?

  4. Zacks Investment Research Upgrades Sanofi (SNY) to "Hold"Read the original story w/Photo

    Friday Jun 15 | Daily Political

    According to Zacks, "Sanofi has several new products in its portfolio and candidates in its pipeline that can contribute to long-term growth. Particularly, we are optimistic on sales prospects of Dupixent, which could prove to be an important growth driver.

    Comment?

  5. Diabetes Putting Millions Of Americans At Risk, Prescription Hope, Inc. Comes To The RescueRead the original story w/Photo

    Tuesday Jun 12 | PRWeb

    Prescription Hope offers over 1,500 brand-name medications all for the set price of $50 per month for each medication. After years of rising prices, insulin costs in the United States are presenting extremely painful choices for people with diabetes and their families.

    Comment?

  6. Humalog (lispro) for type 2 diabetes.Read the original story

    Saturday Jun 9 | CiteULike

    Type 2 diabetes is a chronic and progressive disease, and ultimately, most patients will require insulin therapy for the optimization of their glycemic control. We review the recent literature investigating the efficacy and safety of the insulin analogue lispro in type 2 diabetes.

    Comment?

  7. Zealand Pharma/S (Zeal) Stake Lifted by Farallon Capital Management LLCRead the original story w/Photo

    Saturday Jun 9 | IntersportsWire

    Farallon Capital Management LLC lifted its stake in shares of ZEALAND PHARMA/S by 33.1% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission . The firm owned 865,000 shares of the company's stock after acquiring an additional 215,000 shares during the period.

    Comment?

  8. American Diabetes Association 2016Read the original story

    Friday Jun 8 | P&T Community

    The American Diabetes Association's 76th Scientific Sessions drew more than 16,000 diabetes care professionals to New Orleans, Louisiana, June 10-14. The selections below focus on new biosimilars in type-1 and type-2 diabetes; insulin titration; and a diabetes care delivery program that improves outcomes while reducing costs.

    Comment?

  9. Sanofi (SNY) Rating Increased to Hold at Zacks Investment ResearchRead the original story w/Photo

    Friday Jun 8 | IntersportsWire

    According to Zacks, "Sanofi has several new products in its portfolio and candidates in its pipeline that can contribute to long-term growth. Particularly, we are optimistic on sales prospects of Dupixent, which could prove to be an important growth driver.

    Comment?

  10. Equities Research Analysts' Updated EPS Estimates for June, 6th...Read the original story w/Photo

    Wednesday Jun 6 | AmericanBankingNews.com

    They currently have a $41.00 target price on the stock. The analysts wrote, "We believe that clean and consistent quarterly results from the core bank segment is the greatest catalyst for the stock.

    Comment?

  11. How much is too much? Outcomes in patients using high-dose insulin glargine.Read the original story

    Sunday Jun 3 | CiteULike

    To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document. Many patients with type 2 diabetes mellitus do not achieve glycaemic control targets on basal insulin regimens.

    Comment?

  12. Treatment Dosing Patterns and Clinical Outcomes for Patients with...Read the original story

    Saturday Jun 2 | CiteULike

    Treatment Dosing Patterns and Clinical Outcomes for Patients with Type 2 Diabetes Starting or Switching to Treatment with Insulin Glargine in a Real-World Setting: A Retrospective Observational Study. Usage patterns and effectiveness of a longer-acting formulation of insulin glargine at a strength of 300 units per milliliter have not been studied in real-world clinical practice.

    Comment?

  13. Real-world evidence concerning clinical and economic outcomes of...Read the original story

    Saturday Jun 2 | CiteULike

    Real-world evidence concerning clinical and economic outcomes of switching to insulin glargine 300 units/mL vs other basal insulins in patients with type 2 diabetes using basal insulin. To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  14. Morning administration of 0.4U/kg/day insulin glargine 300U/mL...Read the original story

    Saturday Jun 2 | CiteULike

    Morning administration of 0.4U/kg/day insulin glargine 300U/mL provides less fluctuating 24-hour pharmacodynamics and more even pharmacokinetic profiles compared with insulin degludec 100U/mL in type 1 diabetes. To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.

    Comment?

  15. Zealand Pharma/S (Zeal) Earning Somewhat Positive Press Coverage, Analysis FindsRead the original story w/Photo

    Saturday Jun 2 | IntersportsWire

    Press coverage about ZEALAND PHARMA/S has been trending somewhat positive on Saturday, Accern reports. The research group scores the sentiment of media coverage by reviewing more than twenty million news and blog sources in real time.

    Comment?

  16. Trial Begins in Insulin Glargine Follow-On Biologics LitigationRead the original story w/Photo

    Friday Jun 1 | JD Supra

    On May 29, 2018, a week-long bench trial began before Judge Andrews in Sanofi-Aventis U.S. LLC v. Merck Sharpe & Dohme Corp. in the District of Delaware.

    Comment?

  17. Adocia, Tonghua Dongbao Expand Global Supply PactRead the original story w/Photo

    Friday Jun 1 | Contract Pharma Breaking News

    ADOCIA has expanded its strategic alliance with Tonghua Dongbao Pharmaceuticals to manufacture and supply insulin lispro and insulin glargine APIs to Adocia worldwide, excluding China. Under the Supply Agreements, Tonghua Dongbao will manufacture and supply insulin lispro and insulin glargine APIs to Adocia, in accordance with Adocia's specifications and quality standards.

    Comment?

  18. Adocia and Tonghua Dongbao Announce Global Supply Agreements for Insulin Lispro and Insulin GlargineRead the original story w/Photo

    Friday Jun 1 | Business Wire

    These agreements expand the previously announced strategic alliance between both companies whereby THDB received licenses to develop and commercialize Adocia's BioChaperoneA Lispro and BioChaperoneA Combo in China and other territories ADOCIA and Tonghua Dongbao Pharmaceuticals announced today an expansion of their strategic alliance with Tonghua Dongbao to manufacture and supply insulin lispro and insulin glargine APIs to Adocia worldwide, excluding China. " We are very pleased to strengthen our strategic alliance with Tonghua Dongbao and enter global supply agreements for insulin lispro and insulin glargine.

    Comment?

  19. Zealand Pharma/S (Zeal) Receives Consensus Rating of "Buy" from AnalystsRead the original story w/Photo

    Sunday May 27 | IntersportsWire

    ZEALAND PHARMA/S has been given a consensus recommendation of "Buy" by the six research firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company.

    Comment?

  20. Delaware Court Denies Merck Summary Judgment Motion in Insulin Glargine CaseRead the original story w/Photo

    May 24, 2018 | JD Supra

    As we previously reported , Sanofi-Aventis sued Merck Sharp & Dohme in the District of Delaware for patent infringement based on Merck's proposed follow-on biologics of Sanofi-Aventis's Lantus and Lantus SoloSTAR prefilled cartridge products. On January 2, 2018, Merck moved for summary judgment of non-infringement on the grounds of patent exhaustion and implied license.

    Comment?